Terns Pharmaceuticals
TERN
Market cap $340M

4.00 USD

-0.13

3.15%

At close Feb 21, 4:00 PM EST

After hours

4.13

+0.13

3.25%

1 day

-3.15%

5 days

-2.20%

1 month

-10.11%

3 months

-29.95%

6 months

-49.24%

Year to date

-29.45%

1 year

-50.50%

5 years

-78.25%

10 years

-78.25%

About: Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.

Employees: 66

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 7,139 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

325% more call options, than puts

Call options by funds: $3.7M | Put options by funds: $869K

103% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 33

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

6.95% more ownership

Funds ownership: 94.21% [Q3] → 101.16% (+6.95%) [Q4]

0% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 35

1% less funds holding

Funds holding: 155 [Q3] → 154 (-1) [Q4]

28% less capital invested

Capital invested by funds: $664M [Q3] → $476M (-$188M) [Q4]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7.50

88%

upside

Avg. target

$15.83

296%

upside

High target

$20

400%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

JMP Securities Silvan Tuerkcan 32% 1-year accuracy 18 / 56 met price target	400%upside $20	Market Outperform Reiterated	4 Dec 2024
HC Wainwright & Co. Ed Arce 54% 1-year accuracy 91 / 167 met price target	88%upside $7.50	Neutral Reiterated	4 Dec 2024
Oppenheimer Jay Olson 23% 1-year accuracy 23 / 101 met price target	400%upside $20	Outperform Maintained	4 Dec 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about TERN published over the past 30 days

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise Seasoned biotechnology CEO brings 25 years of strategic, operational and commercial expertise

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:00 p.m. ET.

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of February 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Terns.

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

FOSTER CITY, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025 at 4:30 p.m. PT.

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of January 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”). The equity award was approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee's acceptance of employment with Terns.

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Terns's stock soars as analysts cheer leukemia data — and predict more gains

The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill.

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Terns Pharmaceuticals Inc.'s stock jumped 7.5% premarket Tuesday, after the company announced positive data from an early-stage trial of a treatment for chronic myeloid leukemia.

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of December 1, 2024 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the “Inducement Plan”).

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Top 3 Health Care Stocks You'll Regret Missing In Q4

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks You'll Regret Missing In Q4

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience Accomplished biotechnology CEO brings 25 years of strategic, operational, and legal experience

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

See News Rankings

Charts implemented using Lightweight Charts™